By Jeff Montgomery ( May 7, 2021, 9:19 PM EDT) -- Stockholders pressing consolidated, derivative damage claims against CBD drugmaker Zynerba Pharmaceuticals sought preliminary approval Friday for settlement of a federal suit in Delaware targeting damage to the company from undisclosed adverse effects during a drug trial, in a deal that includes a minimum five-year battery of corporate governance reforms....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.